Tag: BioMarin Pharmaceutical

February 21, 2019 Off

BioMarin slashes net loss by third year over year with milestone payments and increase in sales

BioMarin Pharmaceutical’s net loss for 2018 decreased $39.8 million or 34%, to $77.2 million, compared to $117.0 million in 2017, in part due to increase in gross profil of million.

August 2, 2017 Off

BioMarin quarter net loss reduced. Plans to expand gene therapy for hemophilia A

By Dino Mustafić

BioMarin Pharmaceutical said Wednesday it plans to expand its development plan for BMN 270, its investigational gene therapy for hemophilia A, to include an additional Phase 3 study of the 4e13 vg/kg dose from its ongoing open-label Phase 1/2 study of BMN 270.